{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:26:11Z","timestamp":1787113571676,"version":"build-2736575974"},"publisher-location":"New York, NY","reference-count":30,"publisher":"Springer US","isbn-type":[{"value":"9781071652879","type":"print"},{"value":"9781071652886","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5288-6_31","type":"book-chapter","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:50:21Z","timestamp":1787107821000},"page":"455-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intracerebroventricular Administration of Gangliosides for In Vivo Functional Studies in Mice"],"prefix":"10.1007","author":[{"given":"John","family":"Monyror","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Horkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asifa K.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Sipione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"31_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tibs.2015.04.005","volume":"40","author":"RW Ledeen","year":"2015","unstructured":"Ledeen RW, Wu G (2015) The multi-tasked life of GM1 ganglioside, a true factotum of nature. Trends Biochem Sci 40:407\u2013418","journal-title":"Trends Biochem Sci"},{"key":"31_CR2","doi-asserted-by":"publisher","first-page":"572965","DOI":"10.3389\/fnins.2020.572965","volume":"14","author":"S Sipione","year":"2020","unstructured":"Sipione S, Monyror J, Galleguillos D et al (2020) Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci 14:572965","journal-title":"Front Neurosci"},{"key":"31_CR3","doi-asserted-by":"crossref","unstructured":"Galleguillos D, Wang Q, Steinberg N et al (2022) Anti-inflammatory role of GM1 and other gangliosides on microglia. J Neuroinflammation 19:9","DOI":"10.1186\/s12974-021-02374-x"},{"key":"31_CR4","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1523\/JNEUROSCI.6348-09.2010","volume":"30","author":"V Maglione","year":"2010","unstructured":"Maglione V, Marchi P, Di Pardo A et al (2010) Impaired ganglioside metabolism in Huntington\u2019s disease and neuroprotective role of GM1. J Neurosci 30:4072\u20134080","journal-title":"J Neurosci"},{"key":"31_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.15252\/emmm.201707763","volume":"9","author":"M Alpaugh","year":"2017","unstructured":"Alpaugh M, Galleguillos D, Forero J et al (2017) Disease-modifying effects of ganglioside GM1 in Huntington\u2019s disease models. EMBO Mol Med 9:1537\u20131557","journal-title":"EMBO Mol Med"},{"key":"31_CR6","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1073\/pnas.1114502109","volume":"109","author":"A Di Pardo","year":"2012","unstructured":"Di Pardo A, Maglione V, Alpaugh M et al (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci U S A 109:3528\u20133533","journal-title":"Proc Natl Acad Sci U S A"},{"key":"31_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1016\/j.ymthe.2021.06.005","volume":"29","author":"Y Itokazu","year":"2021","unstructured":"Itokazu Y, Fuchigami T, Morgan JC et al (2021) Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse. Mol Ther 29:3059\u20133071","journal-title":"Mol Ther"},{"key":"31_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42847-x","volume":"9","author":"JS Schneider","year":"2019","unstructured":"Schneider JS, Aras R, Williams CK et al (2019) GM1 ganglioside modifies alpha-synuclein toxicity and is neuroprotective in a rat alpha-synuclein model of Parkinson\u2019s disease. Sci Rep 9: 8362","journal-title":"Sci Rep"},{"key":"31_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/jnr.490420113","volume":"42","author":"JS Schneider","year":"1995","unstructured":"Schneider JS, Kean A, DiStefano L (1995) GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J Neurosci Res 42:117\u2013123","journal-title":"J Neurosci Res"},{"key":"31_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.256.5058.843","volume":"256","author":"JS Schneider","year":"1992","unstructured":"Schneider JS, Pope A, Simpson K et al (1992) Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 256:843\u2013846","journal-title":"Science"},{"key":"31_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3389\/fneur.2019.00859","volume":"10","author":"PJ Magistretti","year":"2019","unstructured":"Magistretti PJ, Geisler FH, Schneider JS et al (2019) Gangliosides: treatment avenues in neurodegenerative disease. Front Neurol 10:859","journal-title":"Front Neurol"},{"key":"31_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jns.2010.02.009","volume":"292","author":"JS Schneider","year":"2010","unstructured":"Schneider JS, Sendek S, Daskalakis C et al (2010) GM1 ganglioside in Parkinson\u2019s disease: results of a five year open study. J Neurol Sci 292:45\u201351","journal-title":"J Neurol Sci"},{"key":"31_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jns.2015.06.028","volume":"356","author":"JS Schneider","year":"2015","unstructured":"Schneider JS, Cambi F, Gollomp SM et al (2015) GM1 ganglioside in Parkinson\u2019s disease: pilot study of effects on dopamine transporter binding. J Neurol Sci 356:118\u2013123","journal-title":"J Neurol Sci"},{"key":"31_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1042\/bj2370147","volume":"237","author":"R Ghidoni","year":"1986","unstructured":"Ghidoni R, Trinchera M, Venerando B et al (1986) Incorporation and metabolism of exogenous GM1 ganglioside in rat liver. Biochem J 237:147\u2013155","journal-title":"Biochem J"},{"key":"31_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/jnr.490370310","volume":"37","author":"MF Saulino","year":"1994","unstructured":"Saulino MF, Schengrund CL (1994) Differential accumulation of gangliosides by the brains of MPTP-lesioned mice. J Neurosci Res 37:384\u2013391","journal-title":"J Neurosci Res"},{"key":"31_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF03160083","volume":"21","author":"A Polo","year":"1994","unstructured":"Polo A, Kirschne G, Guidotti A et al (1994) Brain content of glycosphingolipids after oral administration of monosialogangliosides GM1 and LIGA20 to rats. Mol Chem Neuropathol 21:41\u201353","journal-title":"Mol Chem Neuropathol"},{"key":"31_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/acschemneuro.0c00161","volume":"11","author":"E Revunov","year":"2020","unstructured":"Revunov E, Johnstrom P, Arakawa R et al (2020) First radiolabeling of a ganglioside with a positron emitting radionuclide: in vivo PET demonstrates low exposure of radiofluorinated GM1 in non-human primate brain. ACS Chem Neurosci 11:1245\u20131249","journal-title":"ACS Chem Neurosci"},{"key":"31_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/0006-291X(92)90231-9","volume":"189","author":"C Dumontet","year":"1992","unstructured":"Dumontet C, Rebbaa A, Portoukalian J (1992) Kinetics and organ distribution of [14C]-sialic acid-GM3 and [3H]-sphingosine-GM1 after intravenous injection in rats. Biochem Biophys Res Commun 189:1410\u20131416","journal-title":"Biochem Biophys Res Commun"},{"key":"31_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s002329900434","volume":"165","author":"H Fischer","year":"1998","unstructured":"Fischer H, Gottschlich R, Seelig A (1998) Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 165:201\u2013211","journal-title":"J Membr Biol"},{"key":"31_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/10611869808997889","volume":"6","author":"H van de Waterbeemd","year":"1998","unstructured":"van de Waterbeemd H, Camenisch G, Folkers G et al (1998) Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 6:151\u2013165","journal-title":"J Drug Target"},{"key":"31_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3\u201314","journal-title":"NeuroRx"},{"key":"31_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X et al (2023) The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther 8:217","journal-title":"Signal Transduct Target Ther"},{"key":"31_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jns.2012.10.024","volume":"324","author":"JS Schneider","year":"2013","unstructured":"Schneider JS, Gollomp SM, Sendek S et al (2013) A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson\u2019s disease patients. J Neurol Sci 324:140\u2013148","journal-title":"J Neurol Sci"},{"key":"31_CR24","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/WNL.50.6.1630","volume":"50","author":"JS Schneider","year":"1998","unstructured":"Schneider JS, Roeltgen DP, Mancall EL et al (1998) Parkinson\u2019s disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology 50:1630\u20131636","journal-title":"Neurology"},{"key":"31_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/jcbfm.2015.32","volume":"35","author":"MT Gray","year":"2015","unstructured":"Gray MT, Woulfe JM (2015) Striatal blood-brain barrier permeability in Parkinson\u2019s disease. J Cereb Blood Flow Metab 35:747\u2013750","journal-title":"J Cereb Blood Flow Metab"},{"key":"31_CR26","doi-asserted-by":"publisher","first-page":"593026","DOI":"10.3389\/fphys.2020.593026","volume":"11","author":"S Al-Bachari","year":"2020","unstructured":"Al-Bachari S, Naish JH, Parker GJM et al (2020) Blood-brain barrier leakage is increased in Parkinson\u2019s disease. Front Physiol 11:593026","journal-title":"Front Physiol"},{"key":"31_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.20369","volume":"57","author":"R Kortekaas","year":"2005","unstructured":"Kortekaas R, Leenders KL, van Oostrom JC et al. (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176\u2013179","journal-title":"Ann Neurol"},{"key":"31_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","volume":"13","author":"WM Pardridge","year":"2016","unstructured":"Pardridge WM (2016) CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv 13:963\u2013975","journal-title":"Expert Opin Drug Deliv"},{"key":"31_CR29","doi-asserted-by":"crossref","unstructured":"DeVos SL, Miller TM (2013) Direct intraventricular delivery of drugs to the rodent central nervous system. J Vis Exp 75:e50326","DOI":"10.3791\/50326"},{"key":"31_CR30","unstructured":"Pardridge WM (1991) Peptide drug delivery to the brain\/William M. Pardridge. Raven Press, New York"}],"container-title":["Methods in Molecular Biology","Gangliosides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5288-6_31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:03:53Z","timestamp":1787112233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5288-6_31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071652879","9781071652886"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5288-6_31","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"20 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}